Sector revisions Protalix BioTherapeutics, Inc.

Stocks

Market Closed - NYSE 01:30:00 04/09/2026 am IST			5-day change	1st Jan Change
2.620 ^USD	+1.16%		+0.38%	+45.56%

12/08	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
12/08	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	PROTALIX BIOTHERAPEUTICS, INC.							2
	ELI LILLY AND COMPANY							29
	JOHNSON & JOHNSON							22
	ABBVIE INC.							29
	ROCHE HOLDING AG							18
	NOVARTIS AG							21
	ASTRAZENECA PLC							22
	AMGEN INC.							29
	NOVO NORDISK A/S							23
	GILEAD SCIENCES, INC.							27
	PFIZER INC.							26
	VERTEX PHARMACEUTICALS INCORPORATED							26
	BRISTOL-MYERS SQUIBB COMPANY							24
	SANOFI							23
	GSK PLC							20
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							16
	BAYER AG							18
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	TEVA PHARMACEUTICAL INDUSTRIES LIMITED							10
	Average							21
	Weighted average by Cap.							24